Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Reiberger

Showing results (41-50 of 490) with videos related to

Pageof 49
Sort By:
Journal of Clinical and Experimental Hepatology|September 2, 2025
Recanalizing the Path Forward: Revisiting the Role of Portal Vein Recanalization With Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Portal Vein ThrombosisMarlene Hintersteininger, Lukas Hartl, Thomas Reiberger
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer? Authors' replyMathias Jachs, Thomas Reiberger, Peter Ferenci
Cells|November 26, 2022
Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An UpdatePeter Ferenci, Thomas Reiberger, Mathias Jachs
Journal of Hepatology|April 14, 2021
Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease"Benedikt Simbrunner, Dalila Costa, Thomas Reiberger
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 6, 2021
ReplyMattias Mandorfer, Thomas Reiberger, Mathias Jachs
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2025
ReplyThomas Reiberger, Nina Dominik, Michael Trauner
Alimentary Pharmacology & Therapeutics|December 21, 2024
Letter: Insulin-Like Growth Factor-1 in Cirrhosis Is Linked to Hepatic Dysfunction and Fibrogenesis and Predicts Liver-Related MortAlity-Authors' ReplyLukas Hartl, Michael Schwarz, Thomas Reiberger
Alimentary Pharmacology & Therapeutics|January 15, 2023
Letter: chronic HDV infection-is ignorance bliss? Authors' replyMathias Jachs, Thomas Reiberger, Peter Ferenci
Visceral Medicine|October 23, 2018
Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver FailureJonel Trebicka, Thomas Reiberger, Wim Laleman
Alimentary Pharmacology & Therapeutics|May 26, 2026
Editorial: Bile Acids Under Bulevirtide-A Pharmacodynamic Signature, Not a Prognostic Biomarker. Authors' ReplyMarlene Hintersteininger, Thomas Reiberger, Mathias Jachs
Pageof 49

Showing results (41-50 of 490) with videos related to

Sort By:
Pageof 49
Journal of Clinical and Experimental Hepatology|September 2, 2025
Recanalizing the Path Forward: Revisiting the Role of Portal Vein Recanalization With Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Portal Vein ThrombosisMarlene Hintersteininger, Lukas Hartl, Thomas Reiberger
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer? Authors' replyMathias Jachs, Thomas Reiberger, Peter Ferenci
Cells|November 26, 2022
Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An UpdatePeter Ferenci, Thomas Reiberger, Mathias Jachs
Journal of Hepatology|April 14, 2021
Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease"Benedikt Simbrunner, Dalila Costa, Thomas Reiberger
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 6, 2021
ReplyMattias Mandorfer, Thomas Reiberger, Mathias Jachs
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2025
ReplyThomas Reiberger, Nina Dominik, Michael Trauner
Alimentary Pharmacology & Therapeutics|December 21, 2024
Letter: Insulin-Like Growth Factor-1 in Cirrhosis Is Linked to Hepatic Dysfunction and Fibrogenesis and Predicts Liver-Related MortAlity-Authors' ReplyLukas Hartl, Michael Schwarz, Thomas Reiberger
Alimentary Pharmacology & Therapeutics|January 15, 2023
Letter: chronic HDV infection-is ignorance bliss? Authors' replyMathias Jachs, Thomas Reiberger, Peter Ferenci
Visceral Medicine|October 23, 2018
Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver FailureJonel Trebicka, Thomas Reiberger, Wim Laleman
Alimentary Pharmacology & Therapeutics|May 26, 2026
Editorial: Bile Acids Under Bulevirtide-A Pharmacodynamic Signature, Not a Prognostic Biomarker. Authors' ReplyMarlene Hintersteininger, Thomas Reiberger, Mathias Jachs
Pageof 49